Journal of Psychiatry and Neuroscience
May 12, 2023
Nicolas Garel, Christina Rigas, Mona Ben M’rad et al.
3 citations
A 35-year-old female hemodialysis (HD) patient with end-stage renal disease was able to successfully withdraw from benzodiazepines, which had been prescribed for managing psychiatric and pain symptoms, following a mindfulness-based stress reduction (MBSR) intervention. The patient, who had been
Research Square
May 12, 2023
Gabriel Thorens, Louise Penzenstadler, Leonice Furtado et al.
preprint
Abstract Case report of a patient with GAD and claustrophobia who underwent exposure therapy using psilocybin-assisted psychotherapy. The patient had failed to respond to conventional psychotherapeutic treatment. After three sessions of psilocybin-assisted psychotherapy, the patient experienced a reduction in anxiety and fear associated with closed spaces, elevators, and planes. The protocol...
Current Psychology
May 11, 2023
Monique Williams, Cynthia Honan, Sarah Skromanis et al.
22 citations
This systematic review aimed to identify 1) the effect of mindfulness training on pre-post measures of anxiety and attention among adults experiencing high levels of generalised anxiety; and 2) the impact of predictors, mediators and moderators on post-intervention changes in anxiety or attention. Trait mindfulness and distress measures were included as secondary outcomes. A systematic search...
Cells
May 10, 2023
Mićo Božić, Samo Pirnat, Katja Fink et al.
A single sub-anesthetic dose of ketamine evokes rapid and long-lasting beneficial effects in patients with a major depressive disorder. However, the mechanisms underlying this effect are unknown. It has been proposed that astrocyte dysregulation of extracellular K+ concentration ([K+]o) alters neuronal excitability, thus contributing to depression. We examined how ketamine affects inwardly...
American Journal of Applied Psychology
May 10, 2023
Ornella Montebarocci, Paola Surcinelli, Sara Giovagnoli
1 citation
The purpose of this study was to investigate the relationship between the subjective experience of dreams, anxiety, and depressive symptoms. Specifically, the study aimed to explore whether the subjective experience of dreams, including how often dreams are remembered, the presence of nightmares, and the way in which a person thinks about dreams, could influence the occurrence of subjective...
medRxiv
May 10, 2023
Victoria di Virgilio, Amir Minerbi, Jagpaul Kaur Deol et al.
preprint
Abstract Background The World Health Organization (WHO) defines wellness as the optimal state of health of individuals and groups. No study to date has identified the impact of psychedelic medicines on optimizing wellness using a dimensional approach. Using this approach, treatment effects can be measured more broadly using a composite score of participants’ global perceptions of change for...
Journal of Humanistic Psychology
May 9, 2023
Sasha D. Strong
2 citations
Psychosocial treatments for bipolar disorder (BD) enhance outcomes. However, more than half of those who receive psychosocial treatment experience residual depression. Mindfulness practice demonstrates benefits for numerous psychological problems, but little research has examined mindfulness-based interventions developed specifically for BD. A qualitative study was conducted to inform a new...
Frontiers in Pharmacology
May 9, 2023
Kabirullah Lutfy, Robert N. Pechnick, Nissar A. Darmani
1 citation
Pharmacology of new psychoactive substancesSeveral classes of novel psychoactive substances have been introduced in illicit markets throughout the world and more are being developed.They present major law enforcement challenges and global public health threats.However, there is limited information on their harmful effects on the central nervous, cardiovascular, respiratory, and gastrointestinal...
Medicina
May 9, 2023
Gniewko Więckiewicz, Julia Marek, Iga Stokłosa et al.
5 citations
Background and Objectives: PolDrugs is the largest Polish naturalistic nationwide survey to present basic demographic and epidemiological data that could potentially prevent harm from illicit substances intake in drugs users. The most recent results were presented in 2021. The goal of this year’s edition was to re-present the above data and compare it to the previous edition’s data to identify...
Australian & New Zealand Journal of Psychiatry
May 6, 2023
Julia Lappin, Shane Darke, Michael Farrell
Australian & New Zealand Journal of Psychiatry, 57(6) Interest in prescribing psychoactive drugs as treatments for mental health conditions has been highlighted recently by the decision by the Therapeutic Goods Administration (TGA) to permit, from 1 July 2023, authorised psychiatrists to prescribe medicines containing psilocybin for treatment-resistant depression and...